As of Wednesday, January 07, Olema Pharmaceuticals, Inc.’s OLMA share price has surged by 6.59%, which has investors questioning if this is right time to sell.
For patients with higher-grade or progressive IDH -mutant glioma, how do you individualize choice between radiotherapy (RT) ...
CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026Planned milestones include pivotal dose selection, ...
Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and ...
The ratio between two signaling molecules may be a key marker of MS brain inflammation and help identify candidates for BTK ...
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by using the patient's own T-cells to target tumors.
Triple-negative breast cancer (TNBC) is among the most aggressive types of breast cancer, lacking estrogen, progesterone, and ...
The new Phase III study will test calderasib in a chemo-free regimen for G12C-mutated patients regardless of PD-L1 status.
From football fields to military training grounds, head injuries are leaving lasting marks on the brain in ways we're only ...
The FDA has approved Myqorzo (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) ...
As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback